AbbVie (NYSE:ABBV), a United States-based biopharmaceutical company, has reported its financial results for the second quarter ended 30 June 2020, it was reported on Friday.

The firm posted net revenues of USD10.425bn in the second quarter of 2020, up 26.3% compared to the year-ago period of USD8.255bn.

The company reported a net earnings loss of USD739m, diluted loss per share of USD0.46 on a GAAP Basis and an adjusted diluted EPS of USD2.34 in Q2 2020 compared with net earnings loss of USD741m, diluted loss per share of USD0.49 on a GAAP Basis and an adjusted diluted EPS of USD2.26 in Q2 2019.